Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
FBRX 
Forte Biosciences Inc (FBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/06/2026: FBRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $52.25
1 Year Target Price $52.25
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.85% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/06/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 172.07M USD | Price to earnings Ratio - | 1Y Target Price 52.25 |
Price to earnings Ratio - | 1Y Target Price 52.25 | ||
Volume (30-day avg) 4 | Beta 3.3 | 52 Weeks Range 4.90 - 31.27 | Updated Date 11/24/2025 |
52 Weeks Range 4.90 - 31.27 | Updated Date 11/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -40.79% | Return on Equity (TTM) -73.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 202346935 | Price to Sales(TTM) - |
Enterprise Value 202346935 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.87 | Shares Outstanding 12432854 | Shares Floating 10221049 |
Shares Outstanding 12432854 | Shares Floating 10221049 | ||
Percent Insiders 4.97 | Percent Institutions 87.95 |
Upturn AI SWOT
Forte Biosciences Inc
Company Overview
History and Background
Forte Biosciences Inc. was founded in 2015 with the mission to develop innovative dermatological treatments. The company has focused on advancing its lead product candidate through clinical trials. Key milestones include the initiation and progress of its Phase 2b clinical trial for atopic dermatitis.
Core Business Areas
- Dermatology Therapeutics: Forte Biosciences Inc. is primarily focused on the development and commercialization of novel treatments for dermatological conditions. Their main effort is directed towards advancing their proprietary compound, FB-401, through clinical development.
Leadership and Structure
The company is led by a management team with experience in drug development and the pharmaceutical industry. Specific leadership roles and their extensive biographies are typically detailed in investor relations materials and SEC filings.
Top Products and Market Share
Key Offerings
- Description: FB-401 is a proprietary, live biologic therapeutic candidate for the treatment of atopic dermatitis. It is designed to re-establish a healthy skin microbiome. Market share data for a pre-commercial drug candidate is not applicable. Key competitors in the atopic dermatitis market include Sanofi Genzyme/Regeneron (Dupixent), AbbVie (Skyrizi), Pfizer (Eucrisa), and Lilly (Olumiant).
- Product Name 1: FB-401
Market Dynamics
Industry Overview
The dermatology therapeutics market is a significant and growing sector within the pharmaceutical industry, driven by an increasing prevalence of skin conditions, rising consumer awareness, and advancements in treatment modalities. The biologics and microbiome-focused segments are particularly dynamic.
Positioning
Forte Biosciences Inc. positions itself as a developer of novel, microbiome-based therapies aiming to address unmet needs in dermatology. Their unique approach with a live biologic differentiates them from many established treatments. Their competitive advantage lies in the potential for a novel mechanism of action and a favorable safety profile.
Total Addressable Market (TAM)
The global market for atopic dermatitis treatments is substantial, projected to reach tens of billions of dollars in the coming years. Forte Biosciences Inc. aims to capture a portion of this market with FB-401, but its current position is pre-commercial, and its ultimate market share will depend on successful clinical development, regulatory approval, and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary, novel therapeutic approach (live biologic, microbiome-focused)
- Experienced management team
- Advancement into later-stage clinical trials (Phase 2b)
Weaknesses
- Pre-commercial stage, no approved products
- Reliance on a single lead product candidate
- Potential manufacturing and scalability challenges for a live biologic
Opportunities
- Significant unmet need in dermatology, particularly atopic dermatitis
- Growing interest and investment in microbiome-based therapies
- Potential for strategic partnerships or acquisition by larger pharmaceutical companies
Threats
- Clinical trial failures or delays
- Regulatory hurdles and approval challenges
- Competition from existing and emerging therapies
- Funding challenges for ongoing development
Competitors and Market Share
Key Competitors
- Regeneron Pharmaceuticals, Inc. (REGN)
- AbbVie Inc. (ABBV)
- Pfizer Inc. (PFE)
- Eli Lilly and Company (LLY)
Competitive Landscape
Forte Biosciences Inc. faces established competitors with significant market share and resources in the atopic dermatitis space. Their advantage lies in a potentially novel mechanism of action. However, they lack the established commercial infrastructure and product portfolio of larger players.
Growth Trajectory and Initiatives
Historical Growth: Growth has been characterized by the advancement of its product pipeline and the expansion of its clinical operations, rather than revenue-based growth. Funding rounds have also been a key aspect of its historical financial growth.
Future Projections: Future projections are highly dependent on the successful completion of clinical trials, regulatory approval, and market penetration of FB-401. Analyst estimates, if available, would likely focus on potential peak sales and market share upon commercialization.
Recent Initiatives: Recent initiatives would likely include the ongoing Phase 2b clinical trial for FB-401, potential corporate financing activities, and ongoing scientific research and development efforts.
Summary
Forte Biosciences Inc. is a clinical-stage biotechnology company focused on innovative dermatology treatments, particularly FB-401 for atopic dermatitis. While it possesses a unique microbiome-based approach and a promising lead candidate, its pre-commercial status and reliance on a single drug present significant risks. Success hinges on clinical trial outcomes and regulatory approval in a competitive market dominated by larger players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations websites (if available)
- SEC filings (10-K, 10-Q, S-1)
- Financial news and market data providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Industry research reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute investment advice. Financial data and market information are subject to change and may not be exhaustive. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Forte Biosciences Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2017-04-13 | CEO, President & Chairman Dr. Paul A. Wagner Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.fortebiorx.com |
Full time employees 16 | Website https://www.fortebiorx.com | ||
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.